IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re paterit at cation of

KISO et al.

Serial No. 09/857,695

Filed: June 8, 2001

For:

THERAPEUTIC AGENTS FOR HYPERAMMONEMIA

Attorney Docket No. 46219

Group Art Unit: 1623

Examiner: D. Khare

RECEIVED

NOV H & ZEOZ

TRANSMITTAL OF RESPONSE

Assistant Commissioner for Patents Washington, D.C. 20231

Sir:

TECH CENTER 1600/2900

Transmitted herewith is an Response in the above-captioned application. The fee has been calculated as shown below. (Small entity fees indicated in parentheses.)

CLAIMS AS AMENDED						
(1)	(2)	(3)	(4)	(5)	(6)	(7)
	Claims Remaining After Amendment		Highest Number Previously Paid For	Extra Claims	Rate	Fee
Total Claims	18	-	20		18.00	0
(Small Entity)					(9.00)	
Independent claims	9	-	9		84.00	0
(Small Entity)					(42.00)	
Multiple Dependent	0	-	0	0	280.00	0
(Small Entity)					(140.00)	
Extension of Time	One Month		Two Months	Three Months		
Fee	\$110		\$400	\$920)	\$920.00
(Small Entity)	(\$55)		(\$200)	(\$460,)	0
Total		•				\$920.00

The above fees are believed to be correct. However, the Commissioner is hereby authorized to charge any deficiency or credit any overpayment to Deposit Account No. 50-0687 under the above Attorney Docket Number for which purpose this paper is submitted in duplicate.

Respectfully submitted,

Date: November 6, 2002

Paul E. White, Jr.

Reg. No. 32,011 Tel. No. 202-261-1050 Fax No. 202-887-0336

Manelli Denison & Selter, PLLC 2000 M Street, N.W. Suite 700 Washington, D.C. 20036-3307 202.261.1000

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

INTERATENT APPLICATION of

KISO, et al.

Group Art Unit: 1623

Appln. No.: 09/857,695

Examiner: D. Khare

Filed: June 8, 2001

RECEIVED

Title: THERAPEUTIC AGENTS FOR HYPERAMMONEMIA

NOV 0 8 2002

TECH CENTER 1600/2900

November 6, 2002

AMENDMENT

Hon. Commissioner of Patents and Trademarks Washington, D.C. 20231

Sir:

In response to the Office Action dated May 6, 2002, please amend the subject application as follows.

IN THE CLAIMS:

Please amend claims 3, 7, 8, 9, 10, 11 and 13-18 as follows (see the attached Appendix for the changes made to effect the below claims):

Claim 3. (Amended) The blood ammonia lowering agent according to claim 2, wherein said xylooligosaccharide contains at least 30 wt% of xylobiose

Claim 7. (Amended) The therapeutic agent of hyperammonemia according to claim 6, wherein said xylooligosaccharide contains at least 30 wt% of xylobiose.